File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Detailed curriculum vitae of HER2-targeted therapy

TitleDetailed curriculum vitae of HER2-targeted therapy
Authors
Zhang, XNGao, YZhang, XYGuo, NJHou, WQWang, SWZheng, YCWang, NLiu, HMWang, B
KeywordsCancer
HER2
Inhibitor
Resistance
Issue Date20-Apr-2023
PublisherElsevier
Citation
Pharmacology and Therapeutics, 2023, v. 245 How to Cite?
DOI: http://dx.doi.org/10.1016/j.pharmthera.2023.108417
Abstract

With the booming development of precision medicine, molecular targeted therapy has been widely used in clin-ical oncology treatment due to a smaller number of side effects and its superior accuracy compared to that of tra-ditional strategies. Among them, human epidermal growth factor receptor 2 (HER2)-targeted therapy has attracted considerable attention and has been used in the clinical treatment of breast and gastric cancer. Despite excellent clinical effects, HER2-targeted therapy remains in its infancy due to its resulting inherent and acquired resistance. Here, a comprehensive overview of HER2 in numerous cancers is presented, including its biological role, involved signaling pathways, and the status of HER2-targeted therapy


Persistent Identifierhttp://hdl.handle.net/10722/340041
ISSN
0163-7258
2023 Impact Factor: 12.0
2023 SCImago Journal Rankings: 3.150
ISI Accession Number ID
WOS:000985904500001

 

DC FieldValueLanguage
dc.contributor.authorZhang, XN-
dc.contributor.authorGao, Y-
dc.contributor.authorZhang, XY-
dc.contributor.authorGuo, NJ-
dc.contributor.authorHou, WQ-
dc.contributor.authorWang, SW-
dc.contributor.authorZheng, YC-
dc.contributor.authorWang, N-
dc.contributor.authorLiu, HM-
dc.contributor.authorWang, B-
dc.date.accessioned2024-03-11T10:41:14Z-
dc.date.available2024-03-11T10:41:14Z-
dc.date.issued2023-04-20-
dc.identifier.citationPharmacology and Therapeutics, 2023, v. 245-
dc.identifier.issn0163-7258-
dc.identifier.urihttp://hdl.handle.net/10722/340041-
dc.description.abstract<p>With the booming development of precision medicine, molecular targeted therapy has been widely used in clin-ical oncology treatment due to a smaller number of side effects and its superior accuracy compared to that of tra-ditional strategies. Among them, human epidermal growth factor receptor 2 (HER2)-targeted therapy has attracted considerable attention and has been used in the clinical treatment of breast and gastric cancer. Despite excellent clinical effects, HER2-targeted therapy remains in its infancy due to its resulting inherent and acquired resistance. Here, a comprehensive overview of HER2 in numerous cancers is presented, including its biological role, involved signaling pathways, and the status of HER2-targeted therapy</p>-
dc.languageeng-
dc.publisherElsevier-
dc.relation.ispartofPharmacology and Therapeutics-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCancer-
dc.subjectHER2-
dc.subjectInhibitor-
dc.subjectResistance-
dc.titleDetailed curriculum vitae of HER2-targeted therapy-
dc.typeArticle-
dc.identifier.doi10.1016/j.pharmthera.2023.108417-
dc.identifier.pmid37075933-
dc.identifier.scopuseid_2-s2.0-85152748315-
dc.identifier.volume245-
dc.identifier.isiWOS:000985904500001-
dc.publisher.placeOXFORD-
dc.identifier.issnl0163-7258-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats